IndraLab

Statements



reach
"In addition, the MRC PPU International Centre for Kinase Profiling reported in vitro specificity screens for several inhibitors (http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors), showing that MRT67307 not only inhibits IKKepsilon and TBK1 and the AMPK related kinases MARK, MELK and NUAK, but also Mixed Lineage Kinase (MLK) 1 and MLK3, Janus kinase (JAK) 2, and Ca (2+)/calmodulin-dependent protein kinase kinase beta (CamKKbeta)."

reach
"Taken together, these results indicate that MRT67307 inhibits the phospho (Ser418)-CYLD signal independent of its IKKepsilon and TBK1 inhibitory properties."

reach
"Blocking TBK1 and IKKepsilon during transduction of NK cells enabled their efficient transduction by VSV-G LVs as judged by YFPexpression of 40-50%, with half maximal effective concentrations of 1.1 microM (MRT67307), 5 microM (BX-795) and 24.8 microM (amlexanox)."

No evidence text available

reach
"MRT67307 specifically inhibits the IKKepsilon and TBK1 kinases, which are involved in controlling the production of Type1 interferons but also participate in a negative regulatory loop that restricts the extent of activation of the IKK complex [XREF_BIBR] [XREF_BIBR]."

reach
"The IKKepsilon and TBK1 inhibitor MRT67307 inhibits CYLD phosphorylation independent of IKKepsilon and TBK1."

reach
"For example, MRT67307, which is a new TBK1 inhibitor, derivatized from BX795, suppressed TBK1 activity with much higher specificity (IC 50 = 19nM), so that it did not inhibit other kinases such as JNK or p38 [XREF_BIBR]."

reach
"As it was shown previously that MRT67307 can inhibit IKKepsilon and TBK1 at concentrations as low as 1-2 muM, the concentration of 10 muM used may have led to off-target effects."